Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Decitabine for acute myeloid leukemia.

Peter W Marks1

  • 1Department of Internal Medicine, Yale University School of Medicine, 333 Cedar Street, PO Box 208021, New Haven, CT 06520-8021, USA. peter.marks@yale.edu

Expert Review of Anticancer Therapy
|February 29, 2012
PubMed
Summary

Decitabine, a DNA methyltransferase inhibitor, shows promise for treating acute myeloid leukemia, especially in older patients. Ongoing research explores its optimal use and combinations for better outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Importance of Antibody Titer Determination to the Effective Use of Convalescent Plasma.

Current topics in microbiology and immunology·2024
Same author

Achieving Diversity Through Decentralization.

Journal of general internal medicine·2024
Same author

HIV risk behavior profiles among men who have sex with men interested in donating blood: Findings from the Assessing Donor Variability and New Concepts in Eligibility study.

Transfusion·2023
Same author

Benefit-risk assessment of Covid-19 vaccine, MRNA (MRNA-1273) for males age 18-64 years.

Vaccine: X·2023
Same author

End of a Declared Public Health Emergency - Implications for U.S. Emergency Use Authorizations.

The New England journal of medicine·2023
Same author

Bivalent Covid-19 Vaccines.

The New England journal of medicine·2023

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Decitabine is a nucleoside analogue and DNA methyltransferase inhibitor with a long history of antileukemic efficacy.
  • Current standard dosing for acute myeloid leukemia is a 5-day schedule of 20 mg/m(2).

Purpose of the Study:

  • To review the current understanding and ongoing investigations into the use of decitabine for acute myeloid leukemia.
  • To highlight decitabine's role in managing older patients or those unsuitable for intensive therapies.

Main Methods:

  • Review of existing literature and clinical trial data on decitabine in acute myeloid leukemia.
  • Analysis of toxicity profiles and efficacy in specific patient populations.

Main Results:

  • Decitabine demonstrates antileukemic efficacy with relatively modest nonhematologic toxicity in the standard 5-day regimen.
  • It shows particular promise as a single agent for older patients or those not eligible for intensive treatments.

Conclusions:

  • Decitabine is a valuable therapeutic option for acute myeloid leukemia, especially in elderly or frail patients.
  • Further research is needed to determine optimal dosing, predictive response markers, and effective drug combinations.

Related Experiment Videos